Beskrivning
| Land | Finland |
|---|---|
| Lista | Small Cap Helsinki |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Optomed PlcInside Information14 June 2023 at 11.00, Helsinki
Inside information: Optomed announces CEO transition plan
Optomed's current CEO Seppo Kopsala and the Board of Directors have agreed that Kopsala will leave the CEO position once the new CEO is ready to start. Seppo Kopsala is the founder of Optomed, and he has been the Company's CEO since 2005. The Company's Board of Directors has started the process to find a new CEO.
"I have passionately built Optomed for over 15 years, and my background and expertise lie more in product development and startup entrepreneurship. The Company's most significant product development programs are now finishing, and our products are excellent. The next phase will be scaling up the sales. Optomed and its success remain extremely important to me. I will continue to be a shareholder in the Company, and I am willing to be available to the company in a separately agreed role if requested." Seppo Kopsala comments.
"On behalf of the Board, I want to thank Seppo for his strong contribution as the founder of Optomed. The Company has grown from a fledgling startup to a completely new level as Nasdaq Helsinki main listed company. Seppo has also built a motivated organization, ensuring that the Company has good conditions to succeed in the future. This jointly defined timeline is flexible and gives the Company sufficient time to find the best possible successor." Board Chairperson Petri Salonen, comments.
Further enquiries
Seppo Kopsala, CEO, seppo.kopsala@optomed.com
Petri Salonen, Board Chairperson, petri.salonen@optomed.com,tel. +358 50 594 1510
Optomed in Brief
Optomed is a Finnish medical technology company and a leading manufacturer of handheld fundus cameras and screening software. Optomed combines handheld fundus cameras with software and artificial intelligence with the aim to transform the diagnostic process of various diseases, such as rapidly increasing diabetic retinopathy. Optomed has offices in Finland, the US and China and the company's products are sold via various sales channels in over 60 countries globally
www.optomed.com